

Bladder Cancer (Urothelial) Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ Pathology: _____

Stage: __0a __0is __I __II __III __IV __Recurrent

Line of Treatment: __Neoadjuvant/Pre-Op __ Adjuvant/Post-Op __First Line __Second Line __Third Line __Third Line+ __ Maintenance

Goal of Treatment: __Curative __Non-Curative

ECOG Performance Status: __0 __1 __2 __3 __4

Biomarker:

Platinum Resistant/Refractory? __ Yes __ No

Neoadjuvant Therapy | Clinical Stage II, III, or IV without evidence of metastases (cT2, cT3, cT4a, cT4b, M0)

CMV: cisplatin (Platinol), methotrexate, and vinblastine (Velban) 3 cycles

Gemcitabine (Gemzar) and cisplatin (Platinol) 4 cycles

Adjuvant Therapy | Stage I or II after TURBT* or following resection of recurrent or persistent disease

BCG: bacillus calmette-guerin, intravesical

Metastatic Disease | First line therapy (1st line)

Gemcitabine (Gemzar) and cisplatin** (Platinol)

Metastatic Disease | Second line therapy (2nd line)

Gemcitabine (Gemzar)

Paclitaxel (Taxol)

*TURBT: transurethral resection of bladder tumor

** In the setting of recurrent/metastatic disease, a substitution of carboplatin for cisplatin will be considered a Pathway option.

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

